Celcuity Inc. CELC
Set alert
69.13 USD -0.17 -0.25%
At close · Oct 30
69.29 +0.16 +0.23%
After hours · Oct 30, 4:09 PM ET
67.42 Day range 70.43
56.58 52-week range 144.98
- YTD
- -30.69%
- 1 year
- -12.45%
- Open
- 68.47
- Prev close
- 69.30
- Mkt cap
- 3.38B
- Vol
- 700.08K
- Avg vol
- 1.18M
- EPS
- -4.31
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 67.42
- High
- 70.43
- Forward P/E
- -864.13
- Beta
- 0.11
- Short ratio
- 7.39
- Inst. own
- 112.68%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 5, 2026
- 50-d avg
- 78.10
- 200-d avg
- 100.86
- 1y target
- 154.72
1Y chart
Events in this range
- Nov 12, 2025Earnings: -0.92; estimate -1.02; surprise 9.8%
- Mar 25, 2026Earnings: -0.97; estimate -1.06; surprise 8.49%
- May 14, 2026Earnings: -0.97; estimate -1.04; surprise 6.73%
- Aug 13, 2026Earnings: -1.44; estimate -1.16; surprise -24.14%
- Aug 17, 2026Rating: Citizens · Market Outperform → Market Outperform
- Aug 17, 2026Rating: Guggenheim · Buy → Buy
- Sep 17, 2026Rating: JP Morgan · — → Overweight
- Sep 30, 2026Rating: Needham · Buy → Buy
- Oct 21, 2026Rating: TD Cowen · Buy → Buy
- Oct 22, 2026Rating: Cantor Fitzgerald · — → Overweight
Signals (51)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 7, 2026 | 3 weeks ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Sep 2, 2026 | 1 month ago |
| SMA: Bearish | Aug 27, 2026 | 2 months ago |
| SMA: Bullish | Aug 26, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 2 months ago |
| MACD: Sell Signal | Jul 16, 2026 | 3 months ago |
| SMA: Bearish | Jul 15, 2026 | 3 months ago |
| SMA: Bearish | Jul 10, 2026 | 3 months ago |
| SMA: Bullish | Jul 9, 2026 | 3 months ago |
| SMA: Bearish | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bullish | Jun 26, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 23, 2026 | 4 months ago |
| RSI: Oversold | Jun 5, 2026 | 4 months ago |
| SMA: Bearish | Jun 2, 2026 | 5 months ago |
| RSI: Oversold | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | Jun 1, 2026 | 5 months ago |
| MACD: Sell Signal | May 27, 2026 | 5 months ago |
| MACD: Buy Signal | May 20, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| MACD: Buy Signal | May 15, 2026 | 5 months ago |
| MACD: Sell Signal | May 12, 2026 | 5 months ago |
| MACD: Buy Signal | May 4, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 23, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 20, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 19, 2026 | 7 months ago |
| MACD: Buy Signal | Feb 26, 2026 | 8 months ago |
| SMA: Bullish | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 20, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bearish | Feb 10, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Jan 30, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 26, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 15, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| RSI: Overbought | Jan 7, 2026 | 9 months ago |
| RSI: Overbought | Dec 3, 2025 | 11 months ago |
| MACD: Sell Signal | Dec 2, 2025 | 11 months ago |
| MACD: Buy Signal | Nov 12, 2025 | 11 months ago |
| RSI: Overbought | Nov 12, 2025 | 11 months ago |
| MACD: Sell Signal | Nov 7, 2025 | 11 months ago |
Key statistics
- Market cap
- 3.38B
- Enterprise value
- 3.39B
- Trailing P/E
- 0.00
- Forward P/E
- -864.13
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -4.31
- Beta
- 0.11
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -72.00M
- Total cash
- 754.04M
- Total debt
- 754.39M
- Return on equity
- -1433.70%
- Shares outstanding
- 48.93M
- Short % of float
- 31.43%
- 50-day average
- 78.10
- 200-day average
- 100.86
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 154.72 +123.8% upside
Now 69.13
- Target (low)
- 130.00
- Target (mean)
- 154.72
- Target (high)
- 177.00
Ratings (0m) 13 13 buy · 0 hold · 0 sell
- Strong buy3
- Buy10
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 5, 2026
Expected Nov 5, 2026. Consensus EPS estimate -1.51.
Financials — quick view
CELC Revenue — quarterly 0
CELC Net income — quarterly -78.86M
CELC EPS — quarterly -1.44
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 5, 2026 | Sep 30, 2026 | -1.50 | — | — | — |
| Aug 13, 2026 | Jun 30, 2026 | -1.16 | -1.44 | -0.28 | -24.14% |
| May 14, 2026 | Mar 31, 2026 | -1.04 | -0.97 | +0.07 | +6.73% |
| Mar 25, 2026 | Dec 31, 2025 | -1.06 | -0.97 | +0.09 | +8.49% |
| Nov 12, 2025 | Sep 30, 2025 | -1.02 | -0.92 | +0.10 | +9.80% |
| Aug 14, 2025 | Jun 30, 2025 | -0.90 | -1.04 | -0.14 | -15.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Oct 21, 2026 | TD Cowen | reit | Buy | Buy |
| Sep 30, 2026 | Needham | main | Buy | Buy |
| Sep 17, 2026 | JP Morgan | init | — | Overweight |
| Aug 17, 2026 | Guggenheim | main | Buy | Buy |
| Aug 17, 2026 | Citizens | reit | Market Outperform | Market Outperform |
About Celcuity Inc.
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- celcuity.com
News
- Celcuity: Stronger Clinical Evidence, Much Lower Valuation
- Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
- Cantor Fitzgerald Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $140
- Needham Maintains Buy on Celcuity, Lowers Price Target to $134
- Celcuity Announces Commercial Availability Of REVTORPYK In U.S. For People With Hormone Receptor-Positive
- JP Morgan Initiates Coverage On Celcuity with Overweight Rating, Announces Price Target of $157
- 10 Health Care Stocks With Whale Alerts In Today’s Session
- Celcuity Files Supplemental New Drug Application To FDA For REVTORPYK To Treat Breast Cancer
- Guggenheim Maintains Buy on Celcuity, Raises Price Target to $175
- Citizens Reiterates Market Outperform on Celcuity, Maintains $177 Price Target
Your note
Sign in to keep a note on CELC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BAKER BROS ADVISORS L.P. | Unknown | Sale | Jul 13, 2026 | 0 |
| BULLER RICHARD E | Director | Stock Award(Grant) | Jun 4, 2026 | 9,319 |
| DALVEY DAVID F | Director | Stock Award(Grant) | Jun 4, 2026 | 66,530 |
| FURCHT LEO M.D. | Director | Stock Award(Grant) | Jun 4, 2026 | 12,530 |
| HAHNE VICKY | Chief Financial Officer | Stock Award(Grant) | Aug 13, 2026 | 37,808 |
| LAING LANCE G PH.D. | Officer and Director | Stock Award(Grant) | Aug 13, 2026 | 1,271,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Baker Bros. Advisors, LP | 16.18% | 7,915,792 | 547.22M | Jun 29, 2026 |
| Avoro Capital Advisors LLC | 6.95% | 3,400,000 | 235.04M | Jun 29, 2026 |
| RTW Investments LP | 6.75% | 3,304,903 | 228.47M | Jun 29, 2026 |
| Perceptive Advisors Llc | 6.53% | 3,197,200 | 221.02M | Jun 29, 2026 |
| Blackrock Inc. | 6.17% | 3,018,785 | 208.69M | Jun 29, 2026 |
| State Street Corporation | 4.00% | 1,955,304 | 135.17M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.85% | 1,394,056 | 96.37M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 2.45% | 1,197,169 | 82.76M | Sep 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.04% | 996,070 | 68.86M | Sep 29, 2026 |
| Manager Directed Portfolios-Hood River Small-Cap Growth Fund | 1.32% | 648,060 | 44.80M | Jul 30, 2026 |
| Fidelity Select Portfolios-Select Biotechnology Portfolio | 0.98% | 479,203 | 33.13M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 0.89% | 436,212 | 30.16M | Jun 29, 2026 |